Evidence that the Expression of Progesterone-Induced Blocking Factor by Maternal T-Lymphocytes Is Positively Correlated with Conception
Version of Record online: 6 SEP 2011
American Journal of Reproductive Immunology
Volume 38, Issue 1, pages 6–8, July 1997
How to Cite
Check, J. H., Arwitz, M., Gross, J., Szekeres-Bartho, J. and Wu, C. H. (1997), Evidence that the Expression of Progesterone-Induced Blocking Factor by Maternal T-Lymphocytes Is Positively Correlated with Conception. American Journal of Reproductive Immunology, 38: 6–8. doi: 10.1111/j.1600-0897.1997.tb00269.x
- Issue online: 6 SEP 2011
- Version of Record online: 6 SEP 2011
- Accepted November 26, 1996
- Immunomodulatory protein;
- luteal phase
PROBLEM: To compare the expression by T-lymphocytes of an immunomodulatory protein known as progesterone-induced blocking factor (PIBF) in conception versus non-conception cycles even when there has been definite fertilization and embryo formation.
METHOD: PIBF expression on T lymphocytes was measured using an immunohistochemical method with a PIBF-specific polyclonal antibody. These levels were determined in patients undergoing three types of therapy: non-in vitro fertilization (IVF), IVF-embryo transfer (ET), and frozen ET. Sera were drawn 12 days from ovulation in non-IVF cycles or 9 days after ET and were assayed for PIBF and beta human chorionic gonadotropin. Comparison of the frequency of lymphocyte expression of PIBF in pregnant versus non-pregnant women were made.
RESULTS: PIBF was detected in 29.5% of non-pregnant women and 52.5% of pregnant women. There were no differences in PIBF levels by therapy used in non-pregnant cases or in the pregnant group.
CONCLUSION: These data are consistent with the hypothesis that maternal expression of PIBF in T-lymphocytes soon after trophoblast invasion may depend on successful implantation.